Engflag

Enhertu

Quick links to important sections

Enhertu

Enhertu_FR

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Enhertu

What is Enhertu?

Enhertu (fam-trastuzumab deruxtecan-nxki) is a specialized, prescription-only medication classified as a HER2 inhibitor and an Antineoplastic Agent for use in oncology. It represents an advanced type of targeted therapy known as an Antibody-Drug Conjugate (ADC).

Property Description
Active Ingredient Fam-trastuzumab deruxtecan-nxki
Form Lyophilized powder for intravenous infusion
Pharmacological Class Antibody-Drug Conjugate (ADC), Topoisomerase I Inhibitor
General Purpose To target and destroy HER2-expressing cancer cells
Origin Biologically derived antibody linked to a synthetic payload

The Identity of Enhertu: A Targeted Antineoplastic Agent

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Its active component, fam-trastuzumab deruxtecan-nxki, is a single, complex molecule engineered to provide a highly focused anti-cancer effect. The drug is supplied as a lyophilized powder that is prepared and administered exclusively by intravenous infusion. This medicine is recognized as a targeted therapy, which differs from traditional chemotherapy by reducing the systemic exposure to the potent cytotoxic agent.

Composition and Form: What is Fam-trastuzumab Deruxtecan-nxki?

The complex structure of fam-trastuzumab deruxtecan-nxki is defined by three covalently linked parts. The first is the trastuzumab component, a humanized monoclonal antibody that acts as the homing device, specifically binding to the HER2 protein on the tumor cell surface. The second part is the chemotherapy payload, deruxtecan, a potent synthetic exatecan derivative that functions as a Topoisomerase I Inhibitor.

This entire molecule is held together by a special cleavable linker that is stable in the bloodstream but rapidly broken down by enzymes within the cancer cell. This ensures the active payload is only released after successful internalization by the targeted cell, maximizing localized drug activation.

General Purpose: How This Targeted Therapy Works

The general therapeutic purpose of Enhertu is to induce apoptotic cell death in cancer cells by focusing its destructive power on cells that express the HER2 protein. Once the payload is released inside the tumor cell, it causes extensive DNA damage through Topoisomerase I inhibition.

A key differentiating feature is the prominent bystander effect, where the released payload is capable of moving out of the targeted cell to destroy neighboring tumor cells, even those with lower HER2 expression. This mechanism is crucial for combating the heterogeneity often seen in HER2-expressing solid tumors.

Regulatory References

  1. Fam-Trastuzumab Deruxtecan-nxki (NCI Drug Dictionary)

What side effects are possible with Enhertu?

The officially documented safety profile of Enhertu (fam-trastuzumab deruxtecan-nxki) is defined by government regulatory authorities, detailing potential adverse reactions and special safety considerations.

Adverse Reaction Scope

Classification Examples of Documented Effects
Very Common (Affecting ge 1 in 10) Nausea, fatigue, alopecia (hair loss), anemia, neutropenia, leukopenia, decreased appetite, vomiting, diarrhea, stomatitis, increased liver transaminases.
Common (Affecting ge 1 in 100) Thrombocytopenia, headache, constipation, dizziness, musculoskeletal pain, dry eye, vision blurred, infusion-related reactions.

These reactions are grouped by the affected physiological system, including Blood and Lymphatic System Disorders, Gastrointestinal Disorders, Hepatobiliary Disorders, and Respiratory, Thoracic and Mediastinal Disorders.

Serious Adverse Reactions and Restrictions

Regulatory labeling highlights the risk of several serious adverse reactions:

  • Interstitial Lung Disease (ILD)/Pneumonitis: This is a key safety risk that includes reports of fatal cases and can occur at any time during treatment. It requires specific monitoring.
  • Left Ventricular Dysfunction (LVD): Decreases in left ventricular ejection fraction have been documented, requiring assessment and potential discontinuation if specific thresholds are reached.
  • Hepatotoxicity: Liver injury, indicated by elevations in serum transaminases, can be severe.

Population-Specific Safety Considerations

Patients with moderate renal impairment have shown a higher incidence of Grade 1 and 2 ILD/pneumonitis. Patients with hepatic impairment should be closely monitored due to the potential for increased drug exposure. The label advises on the risk of embryo-fetal toxicity if the medicine is administered during pregnancy.

Connection to the Overall Safety Profile

The official safety information structures the understanding of the medicine's risk profile by detailing the frequent, expected adverse events across various organ systems and clearly identifying the rare, but potentially serious, adverse reactions. This regulatory structure confirms the medicine's safety landscape, noting significant pulmonary, hematologic, and cardiac risks.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information

The official prescribing information for Enhertu defines over-exposure management based on the necessary response to severe, dose-limiting toxicities, as no specific antidote is known or documented. Overdose manifestations are centered on serious systemic toxicity affecting the Pulmonary, Cardiovascular, Hematologic, and Hepatic systems.

Documented Overdose Manifestations

Manifestations of severe drug-related toxicity include signs of Interstitial Lung Disease (ILD) or Pneumonitis, which may present as new or worsening cough, dyspnea, or fever, and Symptomatic Congestive Heart Failure (CHF) associated with Left Ventricular Dysfunction. Laboratory findings may include Neutropenia (low white blood cell count) and Increased Liver Function Tests. Over-exposure management is complicated by a higher incidence of serious adverse reactions observed in patients with moderate renal impairment.

Immediate Action and Required Support

Patients must be advised to immediately report new or worsening respiratory or cardiac symptoms. The regulatory requirement is to call or see your healthcare provider right away if symptoms of lung or heart problems develop, as fatal outcomes have been reported. For suspected ILD/Pneumonitis, the mandated supportive measure includes the prompt initiation of systemic corticosteroid treatment, while the general approach is based on symptomatic and supportive treatment. The drug must be permanently discontinued for symptomatic CHF or ILD/Pneumonitis Grade ge 2.

Therapeutic Uses of Enhertu

Enhertu is a targeted therapeutic option relevant for certain advanced cancers that express the HER2 protein, and is applied in addressing conditions marked by increased physiological stress associated with advanced disease.

Targeting Advanced HER2-Expressing Cancers

The medication is used across conditions presenting with advanced HER2-positive breast cancer, gastric cancer, and specific types of Non-Small Cell Lung Cancer (NSCLC) that have a HER2 gene mutation. This treatment is primarily relevant when the disease is unresectable or metastatic (has spread), and is relevant for easing symptoms that create noticeable physiological strain associated with these conditions. This provides support that helps ease the overall symptom burden associated with progressive disease.

Common Scenarios and Core Benefits

Enhertu is often prescribed as a subsequent line of therapy when cancer has progressed despite patients having already received prior treatments, such as other anti-HER2 regimens or chemotherapy. It is applied in addressing symptoms related to physical discomfort and may assist with managing symptom clusters that become more disruptive during flare-ups following therapeutic failure.

“The medication may be part of symptomatic management applied in scenarios where additional therapeutic assistance is required following the use of prior standard treatments.”

Enhertu is also used for tumors with low or ultra-low levels of HER2 expression (HER2-low breast cancer). It is considered relevant for managing tumor-related symptomatic discomfort. This supports the patient during difficult episodes by easing distress and contributing to improved day-to-day comfort during symptomatic periods.

Quick Fact: Supportive Management for Advanced Disease Symptoms
Enhertu helps manage symptomatic discomfort in conditions involving systemic or localized discomfort associated with unresectable and metastatic HER2-expressing solid tumors.

Eligibility and Restrictions for Use

Regulatory agencies strictly define the population eligible to receive Enhertu (fam-trastuzumab deruxtecan-nxki), based primarily on age, tumor status, and pre-existing medical conditions.

Eligibility Scope

Category Regulatory Status
Populations for whom use is allowed Adult patients (age 18 and older) whose tumors are confirmed to express the HER2 protein (HER2-positive, HER2-low, or HER2-ultralow).
Populations for whom use is contraindicated Patients with a known hypersensitivity to the drug's components, and pregnant women due to the high risk of embryo-fetal harm.
Age-related eligibility rules Safety and effectiveness are not established in the pediatric population (under 18 years). No dose adjustment is required for patients ge 65 years, though data is limited for those ge 75 years.
Condition-specific eligibility rules Use is not established in patients with severe renal impairment or severe hepatic impairment due to insufficient clinical data. Careful monitoring is required for moderate impairment.
Eligibility-related restrictions Permanent Discontinuation is mandated if the patient develops symptomatic congestive heart failure or Grade 2 or greater Interstitial Lung Disease (ILD)/pneumonitis. Females and males of reproductive potential must use effective contraception for 7 months and 4 months, respectively, after the last dose.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the officially documented interaction profile for Enhertu (fam-trastuzumab deruxtecan-nxki), based on authoritative government regulatory sources.

Interaction Scope: Officially Documented Statements

The regulatory documents currently do not list specific medicinal products, food, alcohol, or herbal supplements that are known to cause clinically significant drug-drug or product-product interactions with Enhertu. This means:

  • Contraindicated Combinations: No combinations of Enhertu with other medicines are formally classified as prohibited due to interaction risk in the official prescribing information.
  • Metabolic or Transporter Effects: The labels do not describe any clinically relevant interactions mediated by common metabolic enzymes (e.g., CYP) or drug transporters.
  • Timing Restrictions: No mandatory timing separation rules (e.g., “administer X hours apart”) are prescribed for co-administration with other medicines.

Population-Specific Interaction Notes

Interaction-related considerations primarily exist for specific patient populations, focusing on the potential for altered exposure to the drug's cytotoxic payload, deruxtecan (DXd):

Classification Official Regulatory Statement
Moderate Hepatic Impairment Requires close monitoring for increased toxicities due to the potential for increased systemic exposure of the active payload (DXd).
Severe Renal Impairment Patients ( CrCl < 30 mL/min) should be monitored carefully for adverse reactions, as the recommended dosage has not been established for this group.

The overall interaction structure is defined by the absence of specific drug-drug interaction cautions in the regulatory labels. The official profile is primarily structured around the need for careful observation and close monitoring for toxicities in patients with pre-existing moderate liver or severe kidney impairment.

Mechanism of Action

How Enhertu Works

Targeted Delivery of a Cytotoxic Payload

The drug is engineered as a highly selective antibody-drug conjugate (ADC). It uses an antibody component to specifically recognize and bind to the HER2 protein found on the surface of certain cells, enabling the entire molecule to be taken inside the cell (internalized). This targeted mechanism ensures the concentration of the payload is preferentially delivered to HER2-expressing cells.

Intracellular Activation and DNA Damage

Once inside the cell, the drug is activated by specialized enzymes that cleave its connecting linker, releasing the active Topoisomerase I inhibitor (Deruxtecan). This released payload enters the nucleus and disrupts the cell's genetic material by blocking the Topoisomerase I enzyme, leading to lethal DNA breaks and triggering the process of programmed cell death, or apoptosis.

Amplified Cell Elimination (The Bystander Effect)

The cytotoxic payload is membrane-permeable and can diffuse out of the targeted, dying cell to enter and eliminate adjacent, neighboring cells, even those with low or no HER2 expression. This bystander effect contributes to the local elimination of adjacent cells, leading to a physiological reduction in the overall target cell mass.

Dosage and Administration Information

How to Use Enhertu

Enhertu is administered exclusively via intravenous infusion and is prepared and delivered under the supervision of a healthcare professional in a clinical setting. The medicine is supplied as a lyophilized powder that requires specific steps, including reconstitution and subsequent dilution, before infusion. The drug must not be administered as an intravenous push or bolus.

Standard Dosage and Frequency

The use of Enhertu follows a 21-day treatment cycle, with the medicine administered once every three weeks. The initial dosage is strictly weight-based, varying according to the specific indication.

Usage Parameter Official Labeled Instruction
Standard Dose 5.4 mg/kg for most indications (e.g., breast cancer, NSCLC).
Alternative Dose 6.4 mg/kg for locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma.
Frequency Once every 3 weeks.

Administration Protocol

The proper administration of the infusion requires attention to specific procedural conditions, including the use of prophylactic antiemetics before each dose. The first infusion is typically administered over 90 minutes. If the initial infusion is well tolerated, subsequent doses may be delivered over 30 minutes.

To prepare the infusion solution, the medicine must be diluted only in 5% Dextrose Injection (D5W); the use of sodium chloride injection for dilution is strictly prohibited.

Course Duration and Adjustments

Treatment is continued over multiple cycles until the medical team determines that the disease has progressed or if the treatment can no longer be tolerated. If a dose reduction is required during the course of treatment, that reduction is considered permanent, and re-escalation to a previous, higher dose level is not permitted. No initial dose adjustments are required for older adults or patients with mild hepatic impairment.

Recent Clinical Evidence

The understanding of this medicine's potential role in oncology is based on official regulatory documentation describing clinical research, primarily involving randomized controlled trials (RCTs). These studies examine the medicine against other established treatments or standard care to understand patterns related to disease progression and overall survival. Research so far indicates that the evidence landscape varies depending on the specific type of cancer and the stage of the disease that was studied for.

Evidence for Use in HER2-Positive Metastatic Breast Cancer

The research base for this use includes large RCTs comparing the medicine to an existing anti-HER2 treatment (T-DM1). Researchers explored key outcomes such as Progression-Free Survival (PFS) and Overall Survival (OS). Studies observed measurements related to Progression-Free Survival periods. Later data analyses also described patterns related to Overall Survival (OS) measurements. The research helps show what has been observed so far in group patterns, but research does not determine whether an individual will respond similarly.

Evidence for Use in HER2-Low Metastatic Breast Cancer

This block is based on large randomized controlled trials that compared the medicine to standard chemotherapy chosen by physicians for adult patients with HER2-low metastatic breast cancer. Comparative findings described patterns related to Progression-Free Survival (PFS) periods in the hormone receptor-positive subset. Measurements of Overall Survival (OS) were also reported as group patterns across the overall study population.

Evidence for Use in High-Risk Early Breast Cancer

A large randomized controlled trial was studied for this medicine as an adjuvant therapy in patients with high-risk HER2-positive early breast cancer who had residual disease after initial systemic treatment. The primary analysis reported patterns related to Invasive Disease-Free Survival (IDFS) events in the observed population. Studies monitored outcomes related to distant disease recurrence and brain metastasis events, which were also reported in the observed population.

Evidence for Use in Gastric and Gastroesophageal Junction (GEJ) Cancer

Research for this use involved both single-arm Phase 2 trials and later randomized controlled trials in adult patients with HER2-positive gastric or GEJ cancer after prior treatment. Comparative trials described patterns related to Overall Survival (OS) measurements. Earlier evidence was primarily derived from single-arm studies; although subsequent RCTs have provided comparative data, continued collection of long-term data is standard practice to further describe the long-term patterns observed.

How should Enhertu be stored and disposed of?

The storage and disposal of Enhertu must strictly follow regulatory guidelines. Unopened vials must be stored in a refrigerator between 2 C and 8 C (36 F to 46 F) and kept in their original carton to protect from light. Do not freeze the vials. The medicine must be kept out of the sight and reach of children. After preparation, the reconstituted solution and the diluted infusion solution are also subject to strict time limits. The diluted solution is stable for up to 4 hours at room temperature (up to 25 C) or up to 24 hours when refrigerated, and must remain protected from light. Enhertu is classified as a hazardous drug (cytotoxic). Any unused portion must be discarded following applicable special handling and disposal procedures for hazardous medical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Enhertu found in:

A-Z Index: